A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day. Insufficient cortisol activity may lead to dehydration, hypotension, shock, fatigue and hypoglycemia. Excessive cortisol activity, known as hypercortisolism, may lead to hypertension, diabetes, impaired glucose tolerance, obesity, fatty liver disease, depressed mood, psychosis, wasting of the arms and legs, edema, fatigue, insomnia and other problems.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 761M | 761M | 675M | 482M | 402M | 366M |
| Net Income | 98M | 98M | 140M | 105M | 101M | 113M |
| EPS | $0.82 | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
| Free Cash Flow | 142M | 142M | 196M | 127M | 120M | 167M |
| ROIC | 12.7% | 15.5% | 54.2% | 87.6% | 137.8% | 24.9% |
| Gross Margin | 98.3% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% |
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 45M | 45M | 137M | 107M | 113M | 124M |
| Operating Margin | 5.9% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% |
| ROE | 15.2% | 14.8% | 23.6% | 20.9% | 23.1% | 25.0% |
| Shares Outstanding | 120M | 120M | 114M | 112M | 116M | 126M |
CORCEPT THERAPEUTICS INC passes 6 of 9 quality checks, suggesting mixed fundamentals.
CORCEPT THERAPEUTICS INC trades at 53.3x trailing earnings, compared to its 15-year median P/E of 22.3x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 32.8x vs a median of 25.6x. The company's 5-year average ROIC is 64.0% with a gross margin of 98.5%. Total shareholder yield (buybacks) is 3.3%. At current prices, the estimated annualized return to fair value is +7.6%.
CORCEPT THERAPEUTICS INC (CORT) has a current P/E ratio of 53.3, compared to its historical median P/E of 22.3. The stock is currently considered Expensive based on its historical valuation range.
CORCEPT THERAPEUTICS INC (CORT) has a 5-year average return on invested capital (ROIC) of 64.0%. This indicates strong capital allocation and a potential competitive advantage.
CORCEPT THERAPEUTICS INC (CORT) has a market capitalization of $5.2B. It is classified as a mid-cap stock.
CORCEPT THERAPEUTICS INC (CORT) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 3.31%.
Based on historical P/E analysis, CORCEPT THERAPEUTICS INC (CORT) appears expensive. The current P/E of 53.3 is 139% above its historical median of 22.3. The estimated fair value CAGR (P/E method) is 5.2%.
CORCEPT THERAPEUTICS INC (CORT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CORCEPT THERAPEUTICS INC (CORT) reported annual revenue of $761 million in its most recent fiscal year, based on SEC EDGAR filings.
CORCEPT THERAPEUTICS INC (CORT) has a net profit margin of 12.9%. This is a healthy margin.
CORCEPT THERAPEUTICS INC (CORT) generated $142 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CORCEPT THERAPEUTICS INC (CORT) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
CORCEPT THERAPEUTICS INC (CORT) reported earnings per share (EPS) of $0.82 in its most recent fiscal year.
CORCEPT THERAPEUTICS INC (CORT) has a return on equity (ROE) of 14.8%. This indicates moderate shareholder returns.
CORCEPT THERAPEUTICS INC (CORT) has a 5-year average gross margin of 98.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for CORCEPT THERAPEUTICS INC (CORT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CORCEPT THERAPEUTICS INC (CORT) has a book value per share of $5.41, based on its most recent annual SEC filing.